Advances in reducing cardiovascular risk in the management of patients with type 2 diabetes mellitus

Treatment intended to lower cardiovascular (CV) risk in patients with diabetes has always been a primary goal of diabetes treatment. Due to the subdued effects of reducing hemoglobin A1c (HbA1c) on macrovascular complications, controlling other CV risk factors such as hypertension and hyperlipidemia...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autor principal: Ying Hu
Formato: article
Lenguaje:EN
Publicado: KeAi Communications Co., Ltd. 2019
Materias:
Acceso en línea:https://doaj.org/article/629f46516f7f4dd2a8f15300457c6d7d
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:629f46516f7f4dd2a8f15300457c6d7d
record_format dspace
spelling oai:doaj.org-article:629f46516f7f4dd2a8f15300457c6d7d2021-12-02T12:03:47ZAdvances in reducing cardiovascular risk in the management of patients with type 2 diabetes mellitus2095-882X10.1016/j.cdtm.2019.01.001https://doaj.org/article/629f46516f7f4dd2a8f15300457c6d7d2019-03-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2095882X18300653https://doaj.org/toc/2095-882XTreatment intended to lower cardiovascular (CV) risk in patients with diabetes has always been a primary goal of diabetes treatment. Due to the subdued effects of reducing hemoglobin A1c (HbA1c) on macrovascular complications, controlling other CV risk factors such as hypertension and hyperlipidemia instead of hyperglycemia has been the mainstay treatment to improve CV outcome in patients with type 2 diabetes mellitus (T2DM) until recent years. This review is intended to summarize and compare the results from the available cardiovascular outcome trials (CVOTs) for the two classes of glucose lowering drug: sodium-glucose co-transporter 2 inhibitor (SGLT2i) and glucagon-like peptide-1 receptor agonist (GLP-1 RA). The results including the EMPA-REG, CANVAS program and DECLARE-TIMI 58 trials for SGLT2i, and the ELIXA, LEADER, SUSTAIN-6, EXSCEL and HARMONY trials for GLP-1 RA were summarized. The potential mechanisms of these CV beneficial effects and the optimal CV risk reduction treatment in patients with T2DM based on patient risk stratification and evidence from these CVOTs in real-world setting were discussed. Keywords: Type 2 diabetes mellitus (T2DM), Cardiovascular risk, Cardiovascular outcome trial (CVOT), Sodium-glucose co-transporter 2 inhibitor (SGLT2i), Glucagon-like peptide-1 receptor agonist (GLP-1 RA)Ying HuKeAi Communications Co., Ltd.articleMedicine (General)R5-920ENChronic Diseases and Translational Medicine, Vol 5, Iss 1, Pp 25-36 (2019)
institution DOAJ
collection DOAJ
language EN
topic Medicine (General)
R5-920
spellingShingle Medicine (General)
R5-920
Ying Hu
Advances in reducing cardiovascular risk in the management of patients with type 2 diabetes mellitus
description Treatment intended to lower cardiovascular (CV) risk in patients with diabetes has always been a primary goal of diabetes treatment. Due to the subdued effects of reducing hemoglobin A1c (HbA1c) on macrovascular complications, controlling other CV risk factors such as hypertension and hyperlipidemia instead of hyperglycemia has been the mainstay treatment to improve CV outcome in patients with type 2 diabetes mellitus (T2DM) until recent years. This review is intended to summarize and compare the results from the available cardiovascular outcome trials (CVOTs) for the two classes of glucose lowering drug: sodium-glucose co-transporter 2 inhibitor (SGLT2i) and glucagon-like peptide-1 receptor agonist (GLP-1 RA). The results including the EMPA-REG, CANVAS program and DECLARE-TIMI 58 trials for SGLT2i, and the ELIXA, LEADER, SUSTAIN-6, EXSCEL and HARMONY trials for GLP-1 RA were summarized. The potential mechanisms of these CV beneficial effects and the optimal CV risk reduction treatment in patients with T2DM based on patient risk stratification and evidence from these CVOTs in real-world setting were discussed. Keywords: Type 2 diabetes mellitus (T2DM), Cardiovascular risk, Cardiovascular outcome trial (CVOT), Sodium-glucose co-transporter 2 inhibitor (SGLT2i), Glucagon-like peptide-1 receptor agonist (GLP-1 RA)
format article
author Ying Hu
author_facet Ying Hu
author_sort Ying Hu
title Advances in reducing cardiovascular risk in the management of patients with type 2 diabetes mellitus
title_short Advances in reducing cardiovascular risk in the management of patients with type 2 diabetes mellitus
title_full Advances in reducing cardiovascular risk in the management of patients with type 2 diabetes mellitus
title_fullStr Advances in reducing cardiovascular risk in the management of patients with type 2 diabetes mellitus
title_full_unstemmed Advances in reducing cardiovascular risk in the management of patients with type 2 diabetes mellitus
title_sort advances in reducing cardiovascular risk in the management of patients with type 2 diabetes mellitus
publisher KeAi Communications Co., Ltd.
publishDate 2019
url https://doaj.org/article/629f46516f7f4dd2a8f15300457c6d7d
work_keys_str_mv AT yinghu advancesinreducingcardiovascularriskinthemanagementofpatientswithtype2diabetesmellitus
_version_ 1718394693612470272